Becton, Dickinson and Company $BDX Stake Boosted by Fifth Third Bancorp

Fifth Third Bancorp increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.5% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 31,072 shares of the medical instruments supplier’s stock after purchasing an additional 751 shares during the period. Fifth Third Bancorp’s holdings in Becton, Dickinson and Company were worth $5,352,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Becton, Dickinson and Company by 50.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier’s stock worth $18,808,000 after buying an additional 27,581 shares during the period. FORA Capital LLC acquired a new stake in Becton, Dickinson and Company in the first quarter worth $3,458,000. Foster Victor Wealth Advisors LLC acquired a new stake in Becton, Dickinson and Company in the first quarter worth $6,406,000. Finally, GAMMA Investing LLC increased its position in Becton, Dickinson and Company by 29.9% in the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock worth $744,000 after buying an additional 748 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Barclays dropped their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 3rd. Morgan Stanley increased their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Royal Bank Of Canada started coverage on Becton, Dickinson and Company in a research report on Thursday. They issued a “sector perform” rating and a $211.00 target price on the stock. Finally, Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Four research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $213.09.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares of the company’s stock, valued at $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,965 shares of company stock worth $551,536. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $180.86 on Friday. The firm has a market capitalization of $51.84 billion, a price-to-earnings ratio of 32.53, a price-to-earnings-growth ratio of 1.50 and a beta of 0.27. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The stock’s fifty day moving average is $188.15 and its 200-day moving average is $189.25.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. The firm had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.Becton, Dickinson and Company’s revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s payout ratio is presently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.